Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flecainide in ARVC
NCT03685149Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Jul 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of flecainide in arrhythmogenic right ventricular cardiomyopathy (ARVC), sponsored by University of Rochester. Primary endpoint: Number of Ventricular Ectopic Beats Per Day at 7 days. Started Jul 2019; status: completed.
02
Drugs
flecainide
03
Conditions
arrhythmogenic right ventricular cardiomyopathy (ARVC)
Beyond the preview
Go deeper on NCT03685149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685149.